The Effectiveness of New Oral Anticoagulants in the Treatment of Lower Extremity Venous Thrombosis: A Retrospective Clinical Study

Objective: This clinical study included a retrospective evaluation of 138 patients using new oral anticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban) for lower extremity deep vein thrombosis. Methods: 138 patients using new oral anticoagulant drugs were included in the retrospective study. Demographic characteristics, diagnosis and treatment charts, radiological images, epicrisis notes of the patients were recorded. Records of each patient were reviewed during their 12 months of followup. New oral anticoagulant efficacy; It was evaluated by measuring thigh and calf diameters before and after treatment, whether there was recanalization in Doppler USG (recanalization> 75%), recanalization time, bleeding side effects and recovery times with treatment, and recurrence rates. The data were analyzed statistically using a statistics program. Results: A significant difference was found when the mean thigh diameter measurements measured at the beginning of the treatment (Mean +/- SD: 75,41) and the mean thigh diameter measured after the treatment (Mean +/- SD: 54,63) were compared (p<0.05). A significant difference was found when the mean calf diameter measurements (Mean +/- SD: 43.99) measured at the beginning of the treatment and the mean calf diameter measured after the treatment were compared (p<0.05). Posttreatment Doppler USG showed complete recanalization rate in 54% (75 patients) at 3 months and 25% (35 patients) at 6 months. At the end of the 6th month, the total recanalization rate occurred in 80% (110) patients. Conclusions: New oral anticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban) are very effective in the treatment of lower extremity deep venous thrombosis, both in providing recanalization and in terms of clinical improvement in early and midterm.